Home›Drug Pipeline› Meta-analysis shows benzodiazepine receptor PAMs improve sleep but increase long-term COPD risks in patients with insomnia
Meta-analysis shows benzodiazepine receptor PAMs improve sleep but increase long-term COPD risks in patients with insomniaNew drug improves sleep but raises long-term risks for COPD patients
Frontiers in MedicinePublished April 29, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider cautious use of PAMs in COPD with insomnia due to increased long-term mortality and hospitalization risks.
The analysis found significant improvements in sleep metrics during short-term use. Total sleep time showed a significant improvement with a p-value less than 0.00001, while the frequency of awakenings improved significantly with a p-value of 0.005. Sleep efficiency also demonstrated significant improvement with a p-value less than 0.00001. In contrast, FEV1, oxygen saturation (SaO2), and the frequency of apnea events showed no increase in short-term risks, with p-values of 0.59, 0.61, and 0.45 respectively.
Long-term safety data revealed concerning trends. There was a slight reduction in partial pressure of oxygen (PaO2) during sleep with a p-value of 0.008. More critically, long-term use was associated with a significant increase in all-cause mortality (OR = 1.58, 95% CI: 0.95–2.61, p = 0.08), emergency department visits (OR = 1.97, 95% CI: 1.76–2.19, p < 0.00001), outpatient consultations (OR = 2.07, 95% CI: 1.51–2.82, p < 0.00001), and hospitalizations for acute exacerbations of COPD (OR = 1.94, 95% CI: 1.07–3.52, p = 0.03).
The authors note that sample size and setting were not reported. Serious adverse events, discontinuations, and tolerability were not reported. The review concludes that clinical decisions regarding PAMs therapy for COPD patients with insomnia should be made cautiously after thorough evaluation of short-term benefits versus long-term risks.
A meta-analysis looked at benzodiazepine receptor positive allosteric modulators for people with COPD and insomnia. These patients often struggle with poor sleep and breathing issues. The study combined data from multiple sources to see how the drug worked compared to a placebo.
The drug significantly improved total sleep time, reduced the number of times people woke up, and increased sleep efficiency. These short-term benefits were clear and statistically significant. However, the analysis also tracked serious health outcomes over the long term.
Long-term use of the drug was linked to higher risks. People taking it had more emergency department visits, more outpatient consultations, and more hospitalizations for COPD flare-ups. There was also a slight reduction in oxygen levels during sleep and a potential increase in all-cause mortality. The data suggests that while sleep improves quickly, the long-term dangers may outweigh the benefits for some patients.
What this means for you:
This drug helps sleep but increases long-term risks like hospital visits and death for COPD patients.
ObjectiveGiven the high prevalence and clinical significance of insomnia in COPD patients, and the ongoing controversy surrounding benzodiazepine receptor positive allosteric modulators (PAMs) therapy, this study systematically evaluates the dual-temporal (short- and long-term) safety profile of PAMs through simultaneous assessment of therapeutic benefits and multidimensional risks in COPD-insomnia comorbidity.MethodsA systematic review and meta-analysis was conducted following the PRISMA guidelines. Systematic literature searches were performed in the target databases. The primary indicators for short-term efficacy and safety assessment comprised total sleep time (TST), number of awakenings, sleep efficiency, partial pressure of oxygen (PaO2), oxygen saturation (SaO2), FEV1, and frequency of apnea events. All-cause mortality and Emergency department, Outpatient, and Hospitalization for acute exacerbations of COPD (AECOPD) were employed as indicators for long-term efficacy and safety.ResultsIn COPD patients, PAMs demonstrated significant short-term benefits, with notable improvements in TST (p < 0.00001), frequency of awakenings (p = 0.005), and sleep efficiency (p < 0.00001). Compared with placebo, PAMs did not increase short-term risks in terms of FEV1 (p = 0.59), SaO2 (p = 0.61), and frequency of apnea events (p = 0.45); however, they induced a slight reduction in PaO2 (p = 0.008) during sleep. Notably, long-term use of PAMs was associated with a significant increase in adverse respiratory outcomes, including higher mortality (OR = 1.58, 95% CI: 0.95–2.61, p = 0.08), and elevated frequency of emergency department visits (OR = 1.97, 95% CI: 1.76–2.19, p < 0.00001), outpatient consultations (OR = 2.07, 95% CI: 1.51–2.82, p < 0.00001), and hospitalizations (OR = 1.94, 95% CI: 1.07–3.52, p = 0.03) due to AECOPD.ConclusionIn patients with COPD and comorbid insomnia, the short-term use of PAMs demonstrates therapeutic potential for improving sleep quality and enhancing quality of life, while not imposing additional respiratory burden. However, prolonged administration may potentially accelerate COPD disease progression. Clinical decisions regarding PAMs therapy for COPD patients with insomnia should be made cautiously after thorough evaluation of short-term benefits versus long-term risks.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251035164.
